Skip to main content
← All trials
Macular DegenerationVision and hearingDrugPhase 2, Phase 3

What this study is

Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).

Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.

The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.

What's being tested

  • Tiespectus

    Intervention · DRUG

  • Aflibercept

    Intervention · DRUG

Both interventions

Administered by intravitreal (IVT) injection

Study details

Official title
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
Sponsor
EyeBiotech Ltd.
Conditions
Macular Degeneration · Age-Related Macular Degeneration · Choroidal Neovascularization · Wet Macular Degeneration
Enrolling
960 people
Starts
2026-04-15
Est. completion
2028-07-31
Design
Triple-blind, randomized, parallel groups, Phase 2, Phase 3
Record
View on ClinicalTrials.gov ↗